The mitochondrial p53 pathway.

p53 is one of the most mutated tumor suppressors in human cancers and as such has been intensively studied for a long time. p53 is a major orchestrator of the cellular response to a broad array of stress types by regulating apoptosis, cell cycle arrest, senescence, DNA repair and genetic stability. For a long time it was thought that these functions of p53 solely rely on its function as a transcription factor, and numerous p53 target genes have been identified [1]. In the last 8 years however, a novel transcription-independent proapoptotic function mediated by the cytoplasmic pool of p53 has been revealed. p53 participates directly in the intrinsic apoptosis pathway by interacting with the multidomain members of the Bcl-2 family to induce mitochondrial outer membrane permeabilization. Our review will discuss these studies, focusing on recent advances in the field.

[1]  F. Talos,et al.  Mitochondrially targeted p53 has tumor suppressor activities in vivo. , 2005, Cancer research.

[2]  K. Roemer,et al.  Resistance of mitochondrial p53 to dominant inhibition , 2008, Molecular Cancer.

[3]  U. Moll,et al.  The Role of Ubiquitination in the Direct Mitochondrial Death Program of p53 , 2007, Cell cycle.

[4]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[5]  J. Enríquez,et al.  Direct Regulation of Mitochondrial RNA Synthesis by Thyroid Hormone , 1999, Molecular and Cellular Biology.

[6]  W. Ahn,et al.  Adenovirus-mediated p53 treatment enhances photodynamic antitumor response. , 2006, Human gene therapy.

[7]  D. Turnbull,et al.  Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA , 1999, Nature Genetics.

[8]  T. Kuwana,et al.  PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53 , 2005, Science.

[9]  Roland L. Dunbrack,et al.  Oligomerization of BAK by p53 Utilizes Conserved Residues of the p53 DNA Binding Domain* , 2008, Journal of Biological Chemistry.

[10]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[11]  H. Ding,et al.  Oncogene-dependent Regulation of Caspase Activation by p53 Protein in a Cell-free System* , 1998, The Journal of Biological Chemistry.

[12]  Martin Rechsteiner,et al.  Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.

[13]  P. P. Di Fiore,et al.  Distinct monoubiquitin signals in receptor endocytosis. , 2003, Trends in biochemical sciences.

[14]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[15]  N D Marchenko,et al.  Death Signal-induced Localization of p53 Protein to Mitochondria , 2000, The Journal of Biological Chemistry.

[16]  M. Ciotti,et al.  Oxidative stress induces p53‐mediated apoptosis in glia: p53 transcription‐independent way to die , 2004, Journal of neuroscience research.

[17]  P. Chan,et al.  Mitochondrial Translocation of p53 Mediates Release of Cytochrome c and Hippocampal CA1 Neuronal Death after Transient Global Cerebral Ischemia in Rats , 2006, The Journal of Neuroscience.

[18]  E. Shaulian,et al.  Induction of apoptosis in HeLa cells by trans-activation-deficient p53. , 1995, Genes & development.

[19]  T. Knudsen,et al.  Mitochondrial biogenesis , 1988 .

[20]  Roger M Macklis,et al.  Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation , 2006, Nature chemical biology.

[21]  P. P. Di Fiore,et al.  Signaling through monoubiquitination. , 2004, Current topics in microbiology and immunology.

[22]  W. Rom,et al.  Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53 , 2006, Cancer Gene Therapy.

[23]  Zhao-hui Peng,et al.  Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. , 2005, Human gene therapy.

[24]  A. Fersht,et al.  Comparative Biophysical Characterization of p53 with the Pro-apoptotic BAK and the Anti-apoptotic BCL-xL* , 2007, Journal of Biological Chemistry.

[25]  P. Dagher,et al.  P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. , 2003, Journal of the American Society of Nephrology : JASN.

[26]  Shenmin Yin,et al.  Combination gene therapy with p53 and Thoc1/p84 is more effective than either single agent in an animal model of human pancreatic adenocarcinoma. , 2006, International journal of oncology.

[27]  C. Harris,et al.  p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria , 2004, Oncogene.

[28]  Martin Schuler,et al.  Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis , 2004, Science.

[29]  Lorenzo Galluzzi,et al.  Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.

[30]  U. Moll,et al.  p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity , 2008, Cell Research.

[31]  U. Moll,et al.  p53 and Nur77/TR3 – transcription factors that directly target mitochondria for cell death induction , 2006, Oncogene.

[32]  D. George,et al.  Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. , 2007, Genes & development.

[33]  T. Jacks,et al.  Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.

[34]  D. Dobrota,et al.  Effect of Ischemic Preconditioning on Mitochondrial Dysfunction and Mitochondrial P53 Translocation after Transient Global Cerebral Ischemia in Rats , 2007, Neurochemical Research.

[35]  C. Marth,et al.  Why did p53 gene therapy fail in ovarian cancer? , 2003, The Lancet. Oncology.

[36]  M. Oren,et al.  p53 facilitates pRb cleavage in IL‐3‐deprived cells: novel pro‐apoptotic activity of p53 , 1998, The EMBO journal.

[37]  P. Dagher.  Apoptosis in ischemic renal injury: roles of GTP depletion and p53. , 2004, Kidney international.

[38]  K. Roemer,et al.  Identification of a putative p53 binding sequence within the human mitochondrial genome , 2004, FEBS letters.

[39]  J. Roth.  Adenovirus p53 gene therapy , 2006, Expert opinion on biological therapy.

[40]  C. Gustafsson,et al.  Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA , 2002, Nature Genetics.

[41]  A. Gunasekera,et al.  Defining the p53 DNA‐binding domain/Bcl‐xL‐binding interface using NMR , 2004, FEBS letters.

[42]  F. Casas,et al.  Endocrine regulation of mitochondrial activity: involvement of truncated RXRα and c‐Erb Aαl proteins , 2003 .

[43]  H. Itoh,et al.  P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. , 2003, Cancer research.

[44]  M. Karin,et al.  p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes , 1994, Nature.

[45]  G. Achanta,et al.  Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol γ , 2005, The EMBO journal.

[46]  U. Moll,et al.  The post-translational phosphorylation and acetylation modification profile is not the determining factor in targeting endogenous stress-induced p53 to mitochondria , 2005, Cell Death and Differentiation.

[47]  C. Prives,et al.  Transcriptional regulation by p53: one protein, many possibilities , 2006, Cell Death and Differentiation.

[48]  G. Herrera,et al.  P53 Protein Is a Reliable Marker in Identification of Renal Tubular Injury , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[49]  U. Moll,et al.  Monoubiquitylation promotes mitochondrial p53 translocation , 2007, The EMBO journal.

[50]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[51]  Gerard I. Evan,et al.  Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.

[52]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[53]  U. Moll,et al.  In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation , 2004, Molecular and Cellular Biology.

[54]  U. Moll,et al.  Hypoxia death stimulus induces translocation of p53 protein to mitochondria , 2001, FEBS letters.

[55]  U. Moll,et al.  Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo , 2006, Oncogene.

[56]  A. Saito,et al.  Mitochondrial translocation of p53 underlies the selective death of hippocampal CA1 neurons after global cerebral ischaemia. , 2006, Biochemical Society transactions.

[57]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[58]  T. Knudsen,et al.  Altered expression of mitochondrial 16S ribosomal RNA in p53-deficient mouse embryos revealed by differential display. , 1998, Biochimica et biophysica acta.

[59]  U. Moll,et al.  Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model , 2008, Cell cycle.

[60]  M. Nakao,et al.  Transcriptional Blockade Induces p53-dependent Apoptosis Associated with Translocation of p53 to Mitochondria* , 2005, Journal of Biological Chemistry.

[61]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.